Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol

Journal of Clinical Psychiatry

Volumn 69, Issue 2, 2008, Pages 327-328

  Leo, Roberto ^a   Razzini, Cinzia ^a   Di Lorenzo, Giorgio ^a   Bianchi, Francesco ^a   Tesauro, Manfredi ^a   Zanasi, Marco ^a   Siracusano, Alberto ^a   Romeo, Francesco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART DEPOLARIZATION; HUMAN; LETTER; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SCHIZOPHRENIA; SYMPTOM;

EID: 41549167792     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0221d     Document Type: Letter

References (18)

1. Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry 2005;66:1386-1391
2. Novotny T, Florianova A, Ceskova E, et al. Monitoring of QT interval in patients treated with psychotropic drugs. Int J Cardiol 2007;117:329-332
3. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-329
4. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136
5. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-1736
6. Aripiprazole: new drug: just another neuroleptic. Prescrire Int 2005;14:163-167
7. Bogni A, Monshouwer M, Moscone A, et al. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol In Vitro 2005;19:621-629
8. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58:871-885
9. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006;188:281-292
10. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
11. Fayer SA. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol. J Clin Psychopharmacol 1986;6:375-376
12. Kriwisky M, Perry GY, Tarchitsky D, et al. Haloperidol-induced torsades de pointes. Chest 1990;98:482-484
13. Zee-Cheng CS, Mueller CE, Seifert CF, et al. Haloperidol and torsades de pointes. Ann Intern Med 1985;102:418
14. Sharma ND, Rosman HS, Padhi ID, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998;81:238-240
15. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-69
16. Harvey AT, Flockhart D, Gorski JC, et al. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. J Clin Pharmacol 2004;44:1173-1184
17. Kudo S, Odomi M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 1998;54:253-259
18. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999;37:435-456 328-329